クラミジア性子宮頸管炎に対する経口キノロン薬balofloxacinの臨床的検討  [in Japanese] Clincal efficacy of balofloxacin, a newly oral quinolone, against chlamydial cervicitis  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

新規経口用フルオロキノロン, balofloxacin (BLFX) のクラミジア性子宮頸管炎に対する臨床効果について検討した。クラミジア感染症患者10名に本剤, 1日200mgまたは400mg (b. i. d.) を7~10日間経口投与した結果, 感染症状不明確な2例を除き, 8例全てで<I>Chlamydia trachomatis</I> DNAまたは抗原が陰性化した。また, 臨床所見でも症状の改善または消失が全例に認められ, 有効率は100%であった。本剤に起因する副作用や臨床検査値異常変動は全く認められなかった。

Clinical studies were carried out on balofloxacin (BLFX), a new fluoroquinolone antibiotic, against chlamydial infections in patients with cervicitis.<BR>BLFX was administered oraly 200 or 400mg (b. i. d.) for 7-10 days. Two patients with equivocal evidence of chlamydial infection were excluded. <I>Chlamydia trachomatis</I> DNA or antigen disappeared in 8 cases after the treatment, and the bacteriological response was evaluated as eradicated in 8 cases. With reference to the clinical response, the symptoms of infection improved or disappeared in these cases, and the efficacy rate was therefore evaluated as 100%. No adverse reactions or abnormalities in laboratory findings due to the treatment were recognized.

Journal

  • Japanese Journal of Chemotherapy

    Japanese Journal of Chemotherapy 43, 627-629, 1995-11-27

    Japanese Society of Chemotherapy

References:  8

Codes

Page Top